Get the Stockscreener App
13.39
1.40%
-0.19
After Hours:
13.39
Amneal Pharmaceuticals Inc stock is traded at $13.39, with a volume of 863.61K.
It is down -1.40% in the last 24 hours and up +4.28% over the past month.
Amneal Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, markets, and distributes generic pharmaceutical products for various dosage forms and therapeutic areas. It operates through Generic and Specialty Pharma divisions. The company's generics portfolio includes approximately 200 product families marketed in various dosage forms, such as solid oral doses comprising tablets, capsules, and powders; liquids; sterile injectables; nasal sprays; inhalation and respiratory products; ophthalmics; films; transdermal patches; and topicals, as well as soft gel, complex molecule, and drug-device combinations. It is also involved in the development, manufacture, and sale of branded pharmaceutical products primarily for central nervous system disorders and parasitic infections; and biosimilar products. In addition, the company offers licensed and owned, niche, and mature branded products, as well as a pipeline of 505(b)(2) products for various therapeutic areas that primarily includes Unithroid for endocrinologists and primary care physicians through a contracted salesforce. Amneal Pharmaceuticals, Inc. has a partnership agreement with MabXience S.L. for the development of Avastin, a biosimilar bevacizumab. The company has operations in North America, Asia, and Europe. Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey.
See More
Previous Close:
$13.58
Open:
$13.5
24h Volume:
863.61K
Relative Volume:
0.52
Market Cap:
$4.21B
Revenue:
$2.68B
Net Income/Loss:
$-184.45M
P/E Ratio:
-19.68
EPS:
-0.6805
Net Cash Flow:
$229.23M
1W Performance:
-0.15%
1M Performance:
+4.28%
6M Performance:
+65.92%
1Y Performance:
+51.99%
1-Day Range:
$13.30
$13.58
1-Week Range:
$13.08
$13.75
52-Week Range:
$6.685
$13.75
Amneal Pharmaceuticals Inc Stock (AMRX) Company Profile
Name
Amneal Pharmaceuticals Inc
Sector
Phone
908-947-3120
Address
400 Crossing Boulevard, 3rd Floor, Bridgewater
Compare AMRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AMRX
Amneal Pharmaceuticals Inc
|
13.39 | 4.27B | 2.68B | -184.45M | 229.23M | -0.6805 |
|
ZTS
Zoetis Inc
|
124.05 | 54.82B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
16.29 | 50.36B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
10.46 | 46.00B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
31.81 | 36.32B | 16.88B | 666.71M | 251.19M | 0.6132 |
|
UTHR
United Therapeutics Corp
|
468.94 | 20.33B | 3.08B | 1.24B | 1.07B | 25.61 |
Amneal Pharmaceuticals Inc Stock (AMRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-09-25 | Initiated | Barclays | Overweight |
| Jun-06-25 | Initiated | Goldman | Buy |
| Feb-24-25 | Upgrade | JP Morgan | Neutral → Overweight |
| Sep-06-24 | Upgrade | JP Morgan | Underweight → Neutral |
| Apr-07-21 | Resumed | RBC Capital Mkts | Sector Perform |
| Mar-08-21 | Upgrade | Goldman | Sell → Buy |
| Dec-14-20 | Upgrade | Barclays | Equal Weight → Overweight |
| Dec-14-20 | Upgrade | Guggenheim | Neutral → Buy |
| Jul-27-20 | Initiated | Goldman | Sell |
| May-12-20 | Upgrade | Guggenheim | Sell → Neutral |
| Dec-12-19 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Nov-12-19 | Downgrade | JP Morgan | Neutral → Underweight |
| Nov-07-19 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Jul-22-19 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Jul-11-19 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jul-08-19 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Jun-11-19 | Initiated | Barclays | Equal Weight |
| May-21-19 | Upgrade | Raymond James | Mkt Perform → Strong Buy |
| Mar-20-19 | Initiated | SunTrust | Buy |
| Mar-08-19 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Dec-14-18 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Oct-16-18 | Downgrade | SunTrust | Buy → Hold |
| Aug-13-18 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Jul-23-18 | Initiated | Morgan Stanley | Overweight |
| Jun-22-18 | Initiated | B. Riley FBR, Inc. | Buy |
View All
Amneal Pharmaceuticals Inc Stock (AMRX) Latest News
Stock Recap: Is ACAD in a bullish channelJuly 2025 Short Interest & Smart Allocation Stock Reports - baoquankhu1.vn
Has Amneal Pharmaceuticals (AMRX) Outpaced Other Medical Stocks This Year? - Yahoo Finance
Truist raises PT on Amneal Pharmaceuticals (AMRX) to $15 from $14 - MSN
Profit Recap: Is Amneal Pharmaceuticals Inc in a long term uptrend2025 Geopolitical Influence & Advanced Technical Signal Analysis - baoquankhu1.vn
Amneal Pharmaceuticals (NASDAQ:AMRX) Reaches New 12-Month HighHere's Why - MarketBeat
Amneal Pharmaceuticals stock hits 52-week high at $13.48 - Investing.com
Gains Recap: Is Amneal Pharmaceuticals Inc stock undervalued right nowCEO Change & Community Consensus Picks - baoquankhu1.vn
Geopolitics Watch: Should I buy KNTK stock nowWeekly Stock Analysis & Free Weekly Chart Analysis and Trade Guides - baoquankhu1.vn
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
3 Growth Companies With High Insider Ownership And Up To 79% Earnings Growth - simplywall.st
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Sees Large Increase in Short Interest - MarketBeat
Portfolio Recap: Can Amneal Pharmaceuticals Inc be the next market leader2025 Analyst Calls & Free Daily Entry Point Trade Alerts - baoquankhu1.vn
Amneal unveils new brand identity to reimagine access to medicine - MediaNews4U
Should Value Investors Buy Amneal Pharmaceuticals (AMRX) Stock? - sharewise.com
Trade Recap: Is Amneal Pharmaceuticals Inc a potential multi baggerPortfolio Value Report & Real-Time Buy Signal Alerts - baoquankhu1.vn
Aug PostEarnings: Will Fastenal Company benefit from rate cutsRecession Risk & Trade Opportunity Analysis Reports - baoquankhu1.vn
Mycophenolate Pregnancy Registry: Key Insights for Investors - MSN
Is It Too Late To Consider Amneal Pharmaceuticals (AMRX) After Its Strong Multi‑Year Share Price Run - Yahoo Finance
Amneal unveils bold new brand to reimagine what’s possible in making medicine accessible for all - Pharmabiz.com
Amneal Pharmaceuticals Eyes 2026 Growth at JPMorgan, Crexont Sales Seen Doubling in 2025 - Yahoo Finance
Amneal Pharmaceuticals (NASDAQ:AMRX) Issues FY 2025 Earnings Guidance - MarketBeat
Amneal Pharmaceuticals Files Routine Regulation FD Disclosure Report - TipRanks
Amneal Pharma Expects To Meet Or Exceed Its 2025 Full-Year Financial Guidance - TradingView — Track All Markets
Is Amneal Pharmaceuticals Inc a strong candidate for buy and holdOil Prices & Safe Entry Zone Identification - baoquankhu1.vn
Keiferx collaborates with Amneal on KFRX-06 for Parkinson’s - BioWorld MedTech
Truist Raises PT on Amneal Pharmaceuticals (AMRX) to $15 From $14 - Insider Monkey
How interest rate cuts could boost Amneal Pharmaceuticals Inc. stockJuly 2025 Rallies & Free Fast Entry Momentum Trade Alerts - Улправда
Nasdaq Moves: Why Amneal Pharmaceuticals Inc. stock attracts global investorsJuly 2025 Levels & Weekly Stock Breakout Alerts - Улправда
Is Amneal Pharmaceuticals Inc. stock overvalued by current metricsWeekly Investment Recap & Precise Swing Trade Entry Alerts - ulpravda.ru
Will Amneal Pharmaceuticals Inc. stock recover faster than peersStability vs Neutral Overview & HOKA model picks for your routine - ulpravda.ru
Will Amneal Pharmaceuticals Inc. stock deliver strong dividend growthCushioning Options Review & HOKA model picks for your routine - ulpravda.ru
KeifeRx Announces Research Collaboration and Option Agreement with Amneal Pharmaceuticals to Advance - PharmiWeb.com
A Look At Amneal Pharmaceuticals (AMRX) Valuation As Analyst Optimism And Revenue Outlook Support Recent Momentum - Sahm
KeifeRx and Amneal partner on Parkinson’s disease drug development By Investing.com - Investing.com Canada
KeifeRX announces research collaboration & option agreement with Amneal Pharmaceuticals - MarketScreener
KeifeRx Announces Research Collaboration and Option Agreement with Amneal Pharmaceuticals to Advance KFRX06, a Brain-Penetrant LRRK2 Program for Parkinson’s Disease - Business Wire
KeifeRx and Amneal partner on Parkinson’s disease drug development - Investing.com
Can Amneal Pharmaceuticals Inc. stock continue upward trendJuly 2025 Closing Moves & Breakout Confirmation Trade Signals - Улправда
Why Amneal Pharmaceuticals Inc. stock remains a top recommendationMarket Risk Summary & Breakout Confirmation Trade Signals - ulpravda.ru
Smart Money: Will Amneal Pharmaceuticals Inc. stock benefit from upcoming earnings reportsEarnings Miss & AI Enhanced Market Trend Forecasts - ulpravda.ru
Will Amneal Pharmaceuticals Inc. stock benefit from upcoming earnings reports2025 Price Momentum & Growth Oriented Trading Recommendations - ulpravda.ru
Is Amneal Pharmaceuticals Inc. stock vulnerable to regulatory risksTrade Risk Summary & Weekly Market Pulse Alerts - ulpravda.ru
What is the fair value of Amneal Pharmaceuticals Inc. stock nowFinancial Sector Performance & Superior Trading Portfolio - ulpravda.ru
Can This Healthcare Stock Keep Going After a Nearly 70% Surge? - Barchart.com
Truist Financial Maintains Amneal Pharmaceuticals(AMRX.US) With Buy Rating, Raises Target Price to $15 - 富途牛牛
Amneal Pharmaceuticals, Inc. (AMRX) Stock Analysis: Unveiling a 10% Upside Potential Amidst Robust Revenue Growth - DirectorsTalk Interviews
Amneal Pharmaceuticals stock hits 52-week high at $13.04 By Investing.com - Investing.com Canada
Assessing Amneal Pharmaceuticals (AMRX) Valuation After Strong Multi Year Shareholder Returns - Yahoo Finance
Amneal Pharmaceuticals Inc Stock (AMRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.22%
2.08%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):